Colum, Beotai after Junshi/Multi-Jubilee BioTrop2 ADC drug start-up clinical.

On September 15, the Insight database showed that junshi/Multi-Jubilee ADC drug JS108 (DAC-002) Phase I clinically debuted.
this is the fourth domestic into the clinical stage of the Trop2 ADC, after the domestic has been Baiotai, Colum, Yunding Xinyao's same target ADC start clinical.
from: Insight Database () JS108, known as injection recombinant humanized anti-Trop2 monoantimmune-Tub196 coupled agent, is an ADC drug that is anti-Trop2 monoantigen through intelligently connected body-coupled antimicrobladder Tubulysin B similarity, used to treat Trop2 tritone breast cancer, small cell lung cancer, non-small cell lung cancer, pancreatic cancer.
the drug was first developed by Jubilee Bio, and in 2019 Junshi acquired development interests in other Asian countries outside Japan and South Korea with a milestone payment of 30 million head payments of 270 million yuan.
TROP-2 is a single transfilm surface glycoprotein, also known as tumor-related calcium ion signal transducer 2 (TACSTD2), associated with cell cycle protein D1 (cyclin D1) and kinase C phosphate (PKC).
As an important tumor development factor, Trop2 can promote the process of tumor cell proliferation, invasion and metastasis diffusion, and its high expression is closely related to the shortened survival and adverse prognosticity of tumor patients, so it is of great significance to study anti-tumor drugs with Trop2 as the target.
Insight database shows that there are currently 51 ADC drug clinical trials under way in China, of which 11 are already in phase III clinical stage, including TAA013 of Dongyu Pharmaceuticals, Vanchang Bio's Vedixito monoantigen, BAOtai's BAT8001, all targeting HER2 ADCs.
of which wedissito monoanti has submitted a listing application in August.
from: Insight Database () In the ADC clinical trials that have been conducted, there are 4 ADCs with Trop2 targets, including BAT8003 of Baotai, SKB264 of Colum, sacituzumab govitecan of Yunding Pharmaceuticals, and JS108 of Junshi.
three domestic models with the fastest progress in Colum, in the I/II phase of clinical.
from the Insight database () It's worth noting that there are currently five ADCs in the study that target Trop2 worldwide.
only Trop2 ADC drug on the market is Trodelvy, the core product of Immunomedics, which was awarded an exclusive interest in Greater China by Everest Pharmaceuticals for $835 million.
has now launched Phase II Clinical in China and is expected to be listed by the end of 2021 or early 2022, according to a corporate press release.
also joined layout ADC in its $21 billion acquisition of Immunomedics, confirming its potential.
addition, globally, the DS-1062, developed jointly with AstraZeneta, is also the same target ADC.
as of September 16, according to Insight, the number of ADC drugs entering the clinical phase in China is as follows: